SCHEMBL2297149

SCHEMBL2297149

O=[N+]([O-])C=Cc1ccccc1Br

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.58
FBP1 P09467 8/20 0.53
TLR4 O00206 2/20 0.53
TLR2 O60603 2/20 0.53
HSD11B1 P28845 1/20 0.50
PRMT1 Q99873 1/20 0.47
VCP P55072 1/20 0.46
HSP90AA1 P07900 3/20 0.44
ALDH1A1 P00352 4/20 0.43
MAPT P10636 4/20 0.43
LMNA P02545 3/20 0.43
NPSR1 Q6W5P4 3/20 0.43
ATM Q13315 2/20 0.43
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALOX12 P18054 1/20 0.43
NTSR1 P30989 1/20 0.43
CCR6 P51684 1/20 0.43
MCL1 Q07820 1/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2297146 1.00 RXRA (0.58) RXRAFBP1TLR4TLR2HSD11B1
SCHEMBL29742372 1.00 RXRA (0.58) RXRAFBP1TLR4TLR2HSD11B1
SCHEMBL1805953 0.82 RXRA (0.51) RXRAFBP1TLR4TLR2PRMT1
SCHEMBL31627766 0.82 RXRA (0.51) RXRAFBP1TLR4TLR2PRMT1
SCHEMBL17533439 0.82 RXRA (0.51) RXRAFBP1TLR4TLR2PRMT1
SCHEMBL1805948 0.82 RXRA (0.51) RXRAFBP1TLR4TLR2PRMT1
SCHEMBL2118553 0.79 RXRA (0.49) RXRAFBP1TLR4TLR2PRMT1
SCHEMBL2118550 0.79 RXRA (0.49) RXRAFBP1TLR4TLR2PRMT1
SCHEMBL20562851 0.78 RXRA (0.60) RXRAFBP1TLR4TLR2PRMT1
SCHEMBL20562847 0.78 RXRA (0.60) RXRAFBP1TLR4TLR2PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115521208-B Novel coronavirus 3CL protease inhibitor and application 天津科技大学 2023-09-01 CN claimed
CN-115521208-A Novel coronavirus 3CL protease inhibitor and application 天津科技大学 2022-12-27 CN claimed
CN-111116613-B Polysubstituted benzimidazole thiazole and derivative and synthesis method thereof 湘潭大学 2021-04-23 CN claimed
CN-104277072-B A kind of preparation method of (E)-2-aryl vinyl phosphate derivatives JIANGSU CHINASUN SPECIALTY PRODUCTS CO.,LTD. (CN) 2016-04-13 CN claimed
CN-104277072-A Method for preparing (E)-2-aryl vinyl phosphonate derivatives CHINASUN SPECIALTY PRODUCTS CO LTD 2015-01-14 CN claimed
CN-102115446-B Method for catalytically synthesizing chiral curcumin analogs UNIV EAST CHINA SCIENCE & TECH 2014-05-07 CN claimed
CN-102229613-B New process for synthesis of asenapine GROWINGCHEM CO LTD 2013-08-07 CN claimed
EP-0490567-A1 The use of halogen-containing organic stabilizers for 3-isothiazolones ROHM AND HAAS COMPANY (US) 1992-06-17 EP claimed
JP-4217605-A None JP disclosed
JP-3232802-A None JP disclosed
EP-4627896-A2 3D/2D PEROVSKITE SOLAR CELLS ODTÜ-GÜNAM (TR) 2025-10-08 EP disclosed
WO-2024118031-A2 3D/2D PEROVSKITE SOLAR CELLS ODTÜ-GÜNAM (TR) 2024-06-06 WO disclosed
CN-115521208-B Novel coronavirus 3CL protease inhibitor and application 天津科技大学 2023-09-01 CN disclosed
US-11535628-B2 Method for preparation of Asenapine ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) 2022-12-27 US disclosed
EP-0487870-A2 Insecticidal and acaricidal diarylpyrrolecarbonitrile and diarylnitropyrrole compounds AMERICAN CYANAMID COMPANY (US) 1992-06-03 EP disclosed
JP-H03232802-A INDUSTRIAL GERMICIDE AND BACTERIOSTATIC AGENT KATAYAMA CHEM WORKS CO LTD 1991-10-16 JP disclosed
US-4997954-A Process for preparing substituted isoindolinone derivatives SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1991-03-05 US disclosed
EP-0300614-A1 Process for the preparation of substituted indolinone derivatives SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1989-01-25 EP disclosed
US-4561981-A Treatment of fouling with microcapsules CHARACKLIS WILLIAM G 1985-12-31 US disclosed
US-3931220-A FUNGICIDE, BACTERICIDE BAYER AKTIENGESELLSCHAFT (DT) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11535628-B2 Method for preparation of Asenapine CYP3A5, QDPR, SPR RXRA 4508/4885FBP1 3205/4885TLR4 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.